Dr. Imran Khan is a senior scientist at Bristol Myers Squibb (BMS)- one of the leading biopharmaceutical companies globally. He is located in San Diego, and his team focuses on developing biologic-based therapeutics. Dr. Khan's engagement primarily involves Antibody and Protein engineering to develop cancer therapies.

Before BMS, Dr. Khan worked as a staff scientist and postdoc at Hollings Cancer Center, the only NCI-designated cancer center in South Carolina. Here, he worked on the characterization of Monobodies (Mbs) targeting the most potent oncogenic driver RAS. The Mb's that Dr. Khan characterized have helped understand critical chinks in the RAS armory that can potentially be exploited for targeting RAS, which historically has been challenging to target.  Dr. Khan published the Mb work in PNAS, Cell Reports, oncogene, etc., as the lead author. Some of the Mbs he characterized, like NS1, has become one of the most used reagents in the RAS community globally. GlaxoSmithKline (GSK) in the UK and Merck in Singapore and Cambridge Boston have used NS1 either as PROTAC or mRNA therapeutics.

Dr. Khan graduated from the All India Institute of Medical Sciences (AIIMS), New Delhi. During graduate school, his work focused on developing tumor-targeting therapeutic modalities that cater to tumor specificity in delivery and fine-tuned expression. The therapeutic system Dr. Khan generated has been patented by US and European PCT committees and is at the commercialization stage now. Over the years, Dr. Khan's research has focused mainly on developing targeting modalities that can treat various human pathologies.